Physician profile
Todd Eichelberger
NPI 1306232285
$641.26
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50.77 · 2020: $191 · 2021: $371 · 2022: $27.81.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $135.22 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $131.93 | 2019-2021 | |
| Pfizer INC. | $84.15 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $68.95 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.31 | 2021 | |
| Novo Nordisk INC | $44.09 | 2021 | |
| Lilly USA, LLC | $33.53 | 2021 | |
| Biogen, INC. | $22.49 | 2021 | |
| Aytu Biopharma, INC. | $19.05 | 2020 | |
| Amarin Pharma, INC. | $17.30 | 2019 | |
| Allergan, INC. | $16.80 | 2020 | |
| Antares Pharma, INC. | $15.44 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Eichelberger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.